ResMed’s AirTouch N30i Mask Gains 6% Compliance Lift, Noctrix Acquisition Raises Margins
ResMed reported competitive pressures in its US devices segment but highlighted the AirTouch N30i mask’s 6% higher 90-day compliance rate, driving robust mask growth in Europe and Asia. The Noctrix acquisition’s Nidra device is outpacing ResMed margins, while supply-chain optimizations and a shift to sea freight aim for gross-margin accretion through 2030 despite cost inflation.
1. Competitive Dynamics in US Devices Segment
ResMed faces new product launches from rivals in its US devices segment that could pressure market share and profitability, particularly as traditional HME providers raise concerns about the margins on new fabric masks and slow adoption rates.
2. AirTouch N30i Drives Mask Adoption and Compliance
The AirTouch N30i mask has delivered a 6% higher 90-day compliance rate compared with its silicone counterpart, fueling robust mask revenue growth in Western Europe and Asia Pacific through strategic partnerships and omni-channel distribution.
3. Supply Chain Optimizations Target Margin Accretion
ResMed has transitioned from air to sea freight and strengthened its supply chain improvement pipeline, aiming for gross-margin accretion through 2030; component cost enhancements, platform standardization, vendor management and logistics efficiencies underpin this strategy.
4. Strategic Noctrix Acquisition Enhances Restless Leg Device Portfolio
The acquisition of Noctrix Health bolsters ResMed’s portfolio with the Nidra restless leg syndrome device, which is growing faster and delivering higher gross margins; ResMed plans further R&D and SG&A investments alongside reimbursement initiatives despite expected EPS dilution.